Literature DB >> 23987895

A comparison of length of stay, readmission rate, and facility reimbursement after lobectomy of the lung.

Richard K Freeman1, J Russell Dilts, Anthony J Ascioti, Megan Dake, Raja S Mahidhara.   

Abstract

BACKGROUND: Readmission to the hospital has become a focus for payers with the threat of nonpayment for preventable readmissions and a global penalty for excessive readmissions rates. This study compares readmission rates with lengths of stay (LOS) for patients undergoing lobectomy of the lung and the potential impact on reimbursement.
METHODS: The Premier database for a single health system's hospitals was used to identify patients undergoing lobectomy for non-small cell lung cancer by cardiothoracic surgeons over a 5-year period. Charlson comorbidity scores were also calculated. Regression analysis was used to study the relationship between length of stay and readmission rates. A comparison of the effects of LOS and readmission on reimbursement was also performed.
RESULTS: During the study period, 4,296 lobectomies were performed in 61 hospitals within the healthcare system that met the study's inclusion criteria. A readmission was recorded for 289 patients (7%). Factors associated with readmission were length of stay less than 5 days or more than 16 days and age more than 78 years (p = 0.001). An analysis of the effects of LOS and readmission on reimbursement found an extension of LOS was more cost effective than a readmission.
CONCLUSIONS: This review found that mean LOS after lobectomy is negatively associated with readmission rates, with the maximal effect being before postoperative day 5. Furthermore, facility reimbursement was optimized when LOS was extended to minimize the risk of readmission.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  10; 4

Mesh:

Year:  2013        PMID: 23987895     DOI: 10.1016/j.athoracsur.2013.06.053

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  17 in total

Review 1.  What is quality, and can we define it in lung cancer?-the case for quality improvement.

Authors:  Farhood Farjah; Frank C Detterbeck
Journal:  Transl Lung Cancer Res       Date:  2015-08

2.  Thirty-Day Hospital Readmission After Restorative Proctocolectomy and Ileal Pouch Anal Anastomosis for Chronic Ulcerative Colitis at a High-Volume Center.

Authors:  Nicholas P McKenna; Kellie L Mathis; Mohammad Khasawneh; Omair Shariq; Eric J Dozois; David W Larson; Amy L Lightner
Journal:  J Gastrointest Surg       Date:  2017-08-24       Impact factor: 3.452

3.  Socioeconomic Factors Are Associated With Readmission After Lobectomy for Early Stage Lung Cancer.

Authors:  Rachel L Medbery; Theresa W Gillespie; Yuan Liu; Dana C Nickleach; Joseph Lipscomb; Manu S Sancheti; Allan Pickens; Seth D Force; Felix G Fernandez
Journal:  Ann Thorac Surg       Date:  2016-07-29       Impact factor: 4.330

4.  Enhanced recovery after surgery pathways in thoracic surgery, do they end at discharge?

Authors:  Maria Rodriguez; Maria Aymerich
Journal:  Ann Transl Med       Date:  2019-12

5.  Exploring the burden of inpatient readmissions after major cancer surgery.

Authors:  Karyn B Stitzenberg; YunKyung Chang; Angela B Smith; Matthew E Nielsen
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

6.  Readmission predicts 90-day mortality after esophagectomy: Analysis of Surveillance, Epidemiology, and End Results Registry linked to Medicare outcomes.

Authors:  Yinin Hu; Timothy L McMurry; George J Stukenborg; Benjamin D Kozower
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-28       Impact factor: 5.209

7.  Unexpected readmission after lung cancer surgery: A benign event?

Authors:  Varun Puri; Aalok P Patel; Traves D Crabtree; Jennifer M Bell; Stephen R Broderick; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan F Meyers
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-28       Impact factor: 5.209

8.  Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality.

Authors:  Yinin Hu; Timothy L McMurry; James M Isbell; George J Stukenborg; Benjamin D Kozower
Journal:  J Thorac Cardiovasc Surg       Date:  2014-04-18       Impact factor: 5.209

9.  Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study.

Authors:  Daniel R Evans; Alexander L Lazarides; Mark M Cullen; Jason A Somarelli; Dan G Blazer; Julia D Visguass; Brian E Brigman; William C Eward
Journal:  Ann Surg Oncol       Date:  2021-09-27       Impact factor: 5.344

10.  Continuous infusion of high-dose ulinastatin during surgery does not improve early postoperative clinical outcomes in patients undergoing radical lung cancer surgery: A pilot study.

Authors:  Leng Zhou; Haidan Lan; Qinghua Zhou; Xiao Jun Tang; Daxing Zhu; Jianming Yue; Bin Liu
Journal:  Thorac Cancer       Date:  2016-06-13       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.